Strengthening the paediatric clinical trial ecosystem to better inform policy and programmes

James A Berkley1, Judd L Walson2, Glenda Gray3

  • 1Clinical Research Department, KEMRI/Wellcome Trust Research Programme, Kilifi, Kenya; Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK.

PubMed

Insights

Strengthening the global clinical trial infrastructure for children requires addressing equity gaps and improving research. Key actions include aligning priorities, funding, and supporting consortia for more impactful paediatric trials.

Area of Science:

  • Global Health
  • Paediatric Research
  • Clinical Trials Infrastructure

Background:

  • Childhood diseases have significant lifelong impacts on health and society.
  • Substantial knowledge gaps exist regarding the efficacy and safety of paediatric interventions.
  • Children are often marginalized in clinical trials, raising equity concerns.

Purpose of the Study:

  • To develop a shared vision for an effective global clinical trial infrastructure.
  • To identify challenges and propose solutions for strengthening the paediatric clinical trials ecosystem.
  • To outline actions for global, regional, and national institutions to improve paediatric trials.

Main Methods:

  • Convening the first WHO Global Clinical Trials Forum in November 2023.
  • Forming a Paediatric Clinical Trials Working Group with diverse expert representation.
  • Analyzing challenges such as mismatched priorities, funding, risk aversion, and inadequate infrastructure.

Main Results:

  • Identified critical gaps in paediatric intervention knowledge and equity in trial participation.
  • Highlighted challenges including funding disparities, risk aversion, and poor trial design.
  • Proposed solutions focused on aligning priorities, enhancing funding, and supporting regional consortia.

Conclusions:

  • Aligning local and global child health priorities with funding is crucial.
  • Supporting regional consortia can pool resources for larger, more impactful paediatric trials.
  • Clear responsibilities for institutions are needed for prioritization, coordination, funding, and progress tracking.

Related Concept Videos

Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Preclinical Development: Overview01:28

Preclinical Development: Overview

Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...